Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Human Genetics|November 15, 2016
Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized DystoniaMichael Zech, Sylvia Boesch, Esther M Maier, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 8, 2013
Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar linesDoris Hexsel, Cristiano Brum, Carolina Siega, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 27, 2016
Clinical exome sequencing in early-onset generalized dystonia and large-scale resequencing follow-upMichael Zech, Sylvia Boesch, Angela Jochim, et al.
Clinical Neuropharmacology|July 4, 2014
Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropiniroleKarla Eggert, Christian Öhlwein, Jan Kassubek, et al.
Aesthetic Surgery Journal|February 16, 2017
Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled TrialBenjamin Ascher, Philippe Kestemont, Dominique Boineau, et al.
Aesthetic Surgery Journal|September 25, 2019
Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical TrialBenjamin Ascher, Berthold Rzany, Philippe Kestemont, et al.
Aesthetic Surgery Journal|March 21, 2019
Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar LinesBenjamin Ascher, Berthold Rzany, Philippe Kestemont, et al.
Parkinsonism & Related Disorders|July 21, 2015
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendationsClaudia Trenkwalder, K Ray Chaudhuri, Pedro J García Ruiz, et al.
Parkinsonism & Related Disorders|February 21, 2021
Clinically relevant copy-number variants in exome sequencing data of patients with dystoniaMichael Zech, Sylvia Boesch, Matej Škorvánek, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 19, 2016
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced DyskinesiaClaudia Trenkwalder, Daniela Berg, Olivier Rascol, et al.
Pageof 4